F-18FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-Kit-positive tumor patient by imatinib

被引:6
作者
Zaknun, JJ
Kendler, D
Moncayo, R
zur Nedden, D
Virgolini, I
机构
[1] Med Univ Innsbruck, Clin Dept Nucl Med, Innsbruck, Austria
[2] Med Univ Innsbruck, Clin Dept Radiol 2, Innsbruck, Austria
关键词
GIST; imatinib; (18)FDG-PET; peritoneal involvement;
D O I
10.1097/01.rlu.0000182274.86579.65
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Gastrointestinal stromal tumor (GIST) is a rare group of stromal or connective tissue tumors that arises from mesenchymal cells of the gastrointestinal tract characterized by positive expression of c-Kit. Accurate assessment of GIST tumor spread by anatomic imaging techniques can be difficult in poorly defined tumor lesions such as bowel, peritoneal, or bone metastases. Therefore, an under-estimation of tumor burden may result. In addition, such techniques cannot discriminate early tumor response to therapy. In this rare case, baseline F-18 FDG PET imaging proved to be more efficient than CT in delineating the true metastatic tumor burden and the early-on excellent response to medication targeting cellular tyrosine kinase. Copyright © 2005 by Lippincott Williams & Wilkins.
引用
收藏
页码:749 / 751
页数:3
相关论文
共 9 条
[1]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[2]  
Folpe AL, 2000, CLIN CANCER RES, V6, P1279
[3]  
HIGASHI K, 1993, J NUCL MED, V34, P414
[4]   Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. [J].
Joensuu, H ;
Roberts, PJ ;
Sarlomo-Rikala, M ;
Andersson, LC ;
Tervahartiala, P ;
Tuveson, D ;
Silberman, SL ;
Capdeville, R ;
Dimitrijevic, S ;
Druker, B ;
Demetri, GD .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1052-1056
[5]  
MINN H, 1988, CANCER, V61, P1776, DOI 10.1002/1097-0142(19880501)61:9<1776::AID-CNCR2820610909>3.0.CO
[6]  
2-7
[7]  
Rubin BP, 2001, CANCER RES, V61, P8118
[8]   Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors [J].
Singer, S ;
Rubin, BP ;
Lux, ML ;
Chen, CJ ;
Demetri, GD ;
Fletcher, CDM ;
Fletcher, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3898-3905
[9]   18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®) [J].
Stroobants, S ;
Goeminne, J ;
Seegers, M ;
Dimitrijevic, S ;
Dupont, P ;
Nuyts, J ;
Martens, M ;
van den Borne, B ;
Cole, P ;
Sciot, R ;
Dumez, H ;
Silberman, S ;
Mortelmans, L ;
van Oosterom, A .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (14) :2012-2020